
NVCR
NovoCure Limited
$11.95
+$0.49(+4.28%)
43
Overall
60
Value
27
Tech
--
Quality
Market Cap
$1.28B
Volume
1.99M
52W Range
$10.70 - $34.13
Target Price
$25.06
Company Overview
| Mkt Cap | $1.28B | Price | $11.95 |
| Volume | 1.99M | Change | +4.28% |
| P/E Ratio | -7.6 | Open | $11.40 |
| Revenue | $605.2M | Prev Close | $11.46 |
| Net Income | $-168.6M | 52W Range | $10.70 - $34.13 |
| Div Yield | N/A | Target | $25.06 |
| Overall | 43 | Value | 60 |
| Quality | -- | Technical | 27 |
No chart data available
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest News
NovoCure’s Mixed Q3: Growth Amid Challenges
TipRanks Auto-Generated Newsdesk•23 days ago
Novocure Ltd. Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•24 days ago
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVCR | $11.95 | +4.3% | 1.99M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |